Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.49 |
| ▸ | CA2 | P00918 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8062203 | 0.87 | TDP1 (0.59) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL20358461 | 0.87 | MEN1 (0.56) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL23168272 | 0.87 | TDP1 (0.59) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL10190369 | 0.87 | TDP1 (0.59) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL13767609 | 0.85 | MEN1 (0.55) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL22162664 | 0.85 | MEN1 (0.55) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL3082048 | 0.85 | MEN1 (0.55) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL13405019 | 0.84 | MEN1 (0.54) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL13959018 | 0.83 | MEN1 (0.52) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL6244166 | 0.82 | MEN1 (0.62) | MEN1KMT2AGAATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2209776-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDER | Bayer Schering Pharma AG (DE) | 2010-07-28 | — | — | EP | disclosed |
| EP-2084154-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009007026-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008022786-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | MEN1 3362/4885KMT2A 1315/4885GAA 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.